SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hjorth Hansen H)
 

Search: WFRF:(Hjorth Hansen H) > Safety and efficacy...

Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Hjorth-Hansen, H. (author)
St Olavs Hosp, Dept Hematol, PB 8250 Sluppen, NO-7006 Trondheim, Norway.;Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway.,St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway
Stentoft, J. (author)
Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark.,Aarhus University Hospital, Denmark
Richter, J. (author)
Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden.,Skåne University Hospital, Sweden
show more...
Koskenvesa, P. (author)
Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.,University of Helsinki, Finland; Helsinki University Hospital, Sweden
Höglund, Martin (author)
Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
Dreimane, Arta (author)
Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Region Östergötland, Hematologiska kliniken US
Porkka, K. (author)
Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.
Gedde-Dahl, T. (author)
Oslo Univ Hosp, Rikshosp, Dept Hematol, Oslo, Norway.,Oslo University Hospital, Norway
Gjertsen, B. T. (author)
Haukeland Hosp, Hematol Sect, Dept Internal Med, Bergen, Norway.;Univ Bergen, Dept Clin Sci, Bergen, Norway.,Haukeland Hospital, Norway; University of Bergen, Norway
Gruber, F. X. (author)
Univ Hosp North Norway, Dept Hematol, Tromso, Norway.,University Hospital North Norway, Norway
Stenke, L. (author)
Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Stockholm, Sweden.,Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
Eriksson, K. M. (author)
Sunderbysjukhuset, Dept Internal Med, Lulea, Sweden.
Markevarn, B. (author)
Umea Univ Hosp, Dept Hematol, Umea, Sweden.,Umeå University Hospital, Sweden
Lubking, A. (author)
Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.,University of Helsinki, Finland; Helsinki University Hospital, Sweden
Vestergaard, H. (author)
Odense Univ Hosp, Dept Hematol, Odense, Denmark.,Odense University Hospital, Denmark
Udby, L. (author)
Roskilde Hosp, Dept Hematol, Roskilde, Denmark.,Roskilde Hospital, Denmark
Bjerrum, O. W. (author)
Univ Copenhagen Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark.,University of Copenhagen Hospital, Denmark
Persson, Inger (author)
Uppsala universitet,Statistiska institutionen,Uppsala University, Sweden
Mustjoki, S. (author)
Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.;Univ Helsinki, Dept Clin Chem, Helsinki, Finland.,University of Helsinki, Finland; Helsinki University Hospital, Sweden; University of Helsinki, Finland
Olsson-Strömberg, Ulla (author)
Uppsala universitet,Hematologi,University of Uppsala Hospital, Sweden
show less...
St Olavs Hosp, Dept Hematol, PB 8250 Sluppen, NO-7006 Trondheim, Norway;Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway. St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway (creator_code:org_t)
2016-05-02
2016
English.
In: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 30:9, s. 1853-1860
Related links:
https://www.nature.c...
show more...
https://urn.kb.se/re...
https://doi.org/10.1...
https://urn.kb.se/re...
show less...
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Leukemia (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view